地尔硫联合地高辛治疗风湿性心脏病并快速型心房颤动的临床效果

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (493 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Diltiazem combined with Digoxin in the treatment of rheumatic heart disease with rapid atrial fibrillation.Methods Forty patients with rheumatic heart disease and rapid atrial fibrillation admitted into our hospital from January 15^th,2016 to March 12^th,2017 were selected in this study.They were evenly divided into two groups in random,observation group was treated by Diltiazem combined with Digoxin,and control group was only treated by Digoxin.The total clinical effective rate,quality of life,incidence of adverse reactions,and improvement of cardiac function were observed in the two groups.Results The total clinical effective rate was 95.00% in the observation group,much higher than that in the control group accounting for 60.00% (P<0.05).In the observation group,the scores of quality of life including physiological function,social function,psychological function,and material life were (91.44±6.33),(90.26±6.25),(88.43±5.45) points,and (90.35±6.30) points respectively,was higher than that in the control group [(72.45±4.25),(70.15±4.20),(71.21±4.22),(75.34±4.30) points] (P<0.05).The incidence of adverse reactions in the observation group was 5.00%,lower than that in the control group accounting for 35.00% (P<0.05).The improvement of cardiac function in the observation group was 8 cases in grade Ⅰ and 12 cases in grade Ⅱ,which was superior to those in the control group,5 cases in grade Ⅰ and 15 cases in grade Ⅱ(P<0.05).Conclusion Diltiazem combined with Digoxin in the treatment of rheumatic heart disease complicated with rapid atrial fibrillation obtains a remarkable clinical effect,not only ensures the therapeutic effect,but also reduces the incidence of adverse reactions,which has a value for clinical promotion.

Key words： Diltiazem Digoxin Rheumatic heart disease Rapid atrial fibrillation Clinical effect

Received: 27 June 2017

PACS:

R541.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Liang-zhen
	FANG Zhen

Cite this article:

SUN Liang-zhen,FANG Zhen. Clinical effect of Diltiazem combined with Digoxin in the treatment of rheumatic heart disease complicated with rapid atrial fibrillation[J]. 中国当代医药, 2017, 24(24): 66-68.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I24/66

[1]	顾红军,胡志雄,马彩艳.米力农联合地高辛治疗慢性肺源性心脏病的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31（22）：2190-2192.
[2]	刘文洲,周华富,孙宇,等.超级化激活环核苷酸调控通道基因家族-2在风湿性心脏病二尖瓣狭窄伴心房颤动患者右心耳组织中的表达[J].中华实验外科杂志,2014,31（3）：649-651.
[3]	张伟.风湿性心脏病伴房颤患者合用地高辛、胺碘酮、华法林的药物相互作用[J].临床医药文献电子杂志,2016,3（26）：5306-5307.
[4]	薛立光,宗学莉,孙慧琼.胺碘酮治疗风湿性心脏病快速心房颤动的临床价值评估[J].中外医疗,2015,34（26）：116-117.
[5]	盛炜,李力兵,陆江阳.TGF-β、MMPs和TIMPs在风湿性心脏病二尖瓣狭窄合并持续性房颤中的作用[J].解放军医学杂志,2014,39（8）：614-617.
[6]	郭倩玉,卢成志,孔祥荣.风湿性心脏病心房颤动患者左主干栓塞致急性心肌梗死一例[J].中华老年心脑血管病杂志,2013,15（7）：769-769.
[7]	王彬浩,夏云龙.地高辛在心房颤动患者中应用的再评价[J].中国循环杂志,2016,31（2）：195-197.
[8]	邢方凯,丁红涛,赵宏兵.地高辛用于心房颤动患者相关死亡风险的Meta分析[J].重庆医学,2016,45（32）：4524-4526.
[9]	易欣,周艳丽,夏军,等.单核细胞趋化因子-1和核因子κB与风湿性心脏病心房颤动患者心房纤维化的关系[J].中华老年医学杂志,2015,34（4）：365-368.
[10]	张加强,张卫.右美托咪定对风湿性心脏病合并肺高压患者行瓣膜置换术时血流动力学的影响[J].中国医院药学杂志,2014,34（6）：469-472.
[11]	刘寅强,张学玉,蔡乐.昆明市城郊农民风湿性心脏病影响因素研究[J].现代预防医学,2014,41（1）：144-147.
[12]	朱素燕.风湿性心脏病合并肺动脉高压患者1例的药学监护[J].中国临床药理学杂志,2014,30（3）：225-226.
[13]	蒋芳萍,宁靓,杨波.比索洛尔联合常规三联疗法对风湿性心脏瓣膜病合并慢性心力衰竭患者疗效及相关指标的影响[J].中国药房,2016,27（18）：2511-2513.
[14]	张瑞洁.悬吊训练联合穴位推拿按摩治疗风湿性腰痛的疗效观察[J].中华物理医学与康复杂志,2015,37（7）：526-527.
[15]	程苗苗,翁维良.翁维良治疗风湿性心脏病难治性心力衰竭验案[J].中医杂志,2015,56（7）：551-553.